SCHEDULE: Ikarian Capital Discloses 4.99% Stake in IBIO, Inc.

Ikarian Capital, LLC and Neil Shahrestani have filed an amended Schedule 13G, reporting a beneficial ownership of 4.99% in IBIO, Inc.'s common stock.

Summary

• Ikarian Capital, LLC and Neil Shahrestani collectively beneficially own 1,151,051 shares of IBIO, Inc. common stock.
• This ownership represents 4.99% of the outstanding common stock of IBIO, Inc.
• The total beneficial ownership includes 617,327 shares directly held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts.
• Additionally, 533,724 shares are acquirable within 60 days through the exercise of pre-funded and common warrants.
• The exercise of these warrants is subject to a beneficial ownership limitation, preventing the reporting persons from exceeding 4.99% of the outstanding shares.
• The percentage of class is calculated based on 22,487,308 shares of Common Stock outstanding as of November 10, 2025, as disclosed in IBIO's Form 10-Q.
• Ikarian Capital, LLC is an investment adviser, and Neil Shahrestani indirectly controls Ikarian Capital.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a 13G is primarily a factual disclosure, the presence of a specialized investment adviser holding a significant stake (just under the 5% threshold) can be interpreted as a vote of confidence in the issuer, IBIO, Inc. The certification that the investment is for ordinary course business and not for control influence further supports a stable, long-term outlook from the investor's perspective.

Positives

• A significant stake by an investment adviser like Ikarian Capital can signal confidence in IBIO, Inc.'s long-term prospects.
• The investment is stated to be held in the ordinary course of business, not for the purpose of changing or influencing control, which suggests a passive, long-term investment strategy.

Negatives

• The 4.99% beneficial ownership limitation on warrant exercise prevents the reporting persons from easily increasing their stake beyond this threshold without triggering additional disclosure requirements or potential control implications.

Risks

• The beneficial ownership limitation on warrants could restrict the reporting persons' ability to fully capitalize on potential upside if the stock price increases significantly, as they cannot exceed the 4.99% threshold through warrant exercise.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding IBIO, Inc.'s future performance or operations.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This Schedule 13G filing indicates a significant, but passive, investment by an institutional investor in IBIO, Inc. Such filings are common in the investment landscape, providing transparency into large ownership stakes. For a biotechnology company like IBIO, a substantial investment from a specialized healthcare fund like Ikarian Capital can be viewed positively, suggesting a belief in the company's long-term potential within the competitive biotech sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a 4.99% stake may instill confidence and potentially attract other investors, positively impacting share price stability.
• Management: Awareness of a substantial, but passive, institutional investor may influence strategic decisions, though the filing explicitly states no intent to influence control.

Key Dates

Recommendation

The filing indicates a significant, but passive, institutional investment in IBIO, Inc. by Ikarian Capital. While this can be seen as a positive signal of investor confidence, the filing itself does not provide new operational or financial performance data for IBIO, Inc. to warrant a 'buy' or 'sell' recommendation. It primarily updates beneficial ownership. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current position while awaiting further operational updates from IBIO, Inc. to assess its fundamental value.

Keywords

IBIO Inc, Ikarian Capital, Neil Shahrestani, Beneficial Ownership, Schedule 13G, Common Stock, Warrants, Investment Adviser, Healthcare, Biotechnology